Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access